menu
    • menu
    [{"orgOrder":0,"company":"Zura Bio","sponsor":"Zura Bio","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Merger","leadProduct":"ZB-168","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Zura Bio \/ Zura Bio","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ Zura Bio"},{"orgOrder":0,"company":"Zura Bio","sponsor":"JATT Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"ZB-168","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Zura Bio \/ JATT Acquisition","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ JATT Acquisition"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Tibulizumab","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Zura Bio \/ Zura Bio","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ Zura Bio"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"Tibulizumab","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Zura Bio \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ Deep Track Capital"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"Tibulizumab","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Zura Bio \/ Deep Track Capital","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ Deep Track Capital"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Access Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"Tibulizumab","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.11,"dosageForm":"Injection","sponsorNew":"Zura Bio \/ Access Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ Access Biotechnology"},{"orgOrder":0,"company":"Zura Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Tibulizumab","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Zura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Zura Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zura Bio \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Zura Bio

    Menu

    Zura Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zura Bio

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Zura Bio

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tibulizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zura Submits Tibulizumab Phase 2 Protocol for Systemic Sclerosis to FDA

                            Details : Tibulizumab, an investigational humanized, tetravalent bispecific dual-antagonist antibody, designed to neutralize both IL-17A and BAFF, for the treatment of systemic sclerosis (SSc) in adults.

                            Brand Name : ZB-106

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 14, 2024

                            Lead Product(s) : Tibulizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Zura Bio

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Zura Bio

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tibulizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Access Biotechnology

                            Deal Size : $112.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Zura Bio Announces Oversubscribed $112.5 Million Private Placement

                            Details : Net proceeds will accelerate development of ZB-106 (tibulizumab), including a planned Phase 2 trial in systemic sclerosis and another evaluating its use for hidradenitis suppurativa.

                            Brand Name : ZB-106

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 18, 2024

                            Lead Product(s) : Tibulizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Access Biotechnology

                            Deal Size : $112.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Zura Bio

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Zura Bio

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tibulizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Deep Track Capital

                            Deal Size : $80.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-i...

                            Details : The funding will allow Zura Bio to initiate a Phase 2 clinical trial for ZB-106 (tibulizumab), a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist, in systemic sclerosis (SSc), followed by a Phase 2 clinical trial in hidradenitis suppurat...

                            Brand Name : ZB-106

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 06, 2023

                            Lead Product(s) : Tibulizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Deep Track Capital

                            Deal Size : $80.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zura Bio

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Zura Bio

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tibulizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Recipient : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class...

                            Details : Through the agreement, Zura Bio will expand its Immunology pipeline by including ZB-106 (tibulizumab), a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist.

                            Brand Name : ZB-106

                            Molecule Type : Large molecule

                            Upfront Cash : $4.2 million

                            April 27, 2023

                            Lead Product(s) : Tibulizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Recipient : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Zura Bio

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Zura Bio

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tibulizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Deep Track Capital

                            Deal Size : $80.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class...

                            Details : The net proceedings will be used to to initiate a Phase 2 study for ZB-106 (tibulizumab), a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist, in Systemic Sclerosis.

                            Brand Name : ZB-106

                            Molecule Type : Large molecule

                            Upfront Cash : $80.0 million

                            April 27, 2023

                            Lead Product(s) : Tibulizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Deep Track Capital

                            Deal Size : $80.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Zura Bio

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Zura Bio

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZB-168

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : JATT Acquisition

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

                            Details : The combined company will focus on the clinical development of pipeline candidates ZB-168 and torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways.

                            Brand Name : ZB-168

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 21, 2023

                            Lead Product(s) : ZB-168

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : JATT Acquisition

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Zura Bio

                            United Kingdom arrow
                            VMX
                            Not Confirmed

                            Zura Bio

                            United Kingdom arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZB-168

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Recipient : JATT Acquisition Corp

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            JATT Acquisition Corp. and Zura Bio Limited Announce Definitive Business Combination Agreement to Create NYSE ...

                            Details : Proceeds from the transaction are expected to provide Zura Bio with the capital needed to accelerate the development of ZB-168, a fully-human, clinical-stage antibody targeting IL7Rα, that was recently in-licensed from Pfizer Inc.

                            Brand Name : ZB-168

                            Molecule Type : Large molecule

                            Upfront Cash : $65.0 million

                            June 17, 2022

                            Lead Product(s) : ZB-168

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Recipient : JATT Acquisition Corp

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth